Chardan analyst Keay Nakae raised the firm’s price target on ProQR Therapeutics (PRQR) to $4 from $2.50 and keeps a Buy rating on the shares post the Q3 report. The Company’s lead program, AX-0810, targeting NTCP for cholastic disease is poised to enter the clinic, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRQR:
- ProQR Therapeutics Shows Revenue Growth Amid Financial Challenges
- ProQR Therapeutics reports Q3 EPS (EUR 0.10) vs. (EUR 0.07) last year
- ProQR Therapeutics sees cash runway into mid-2027
- PRQR Earnings this Week: How Will it Perform?
- Trade Desk downgraded, First Solar upgraded: Wall Street’s top analyst calls